Senti Biosciences (NASDAQ:SNTI) Posts Quarterly Earnings Results, Misses Expectations By $0.08 EPS

Senti Biosciences (NASDAQ:SNTI) released its quarterly earnings results on Friday. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.08), FiscalAI reports. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.01 million.

Senti Biosciences Stock Performance

Shares of SNTI traded up $0.07 during midday trading on Friday, reaching $0.45. The stock had a trading volume of 603,575 shares, compared to its average volume of 206,848. The firm has a 50 day simple moving average of $0.73 and a 200-day simple moving average of $0.87. Senti Biosciences has a one year low of $0.33 and a one year high of $2.88.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Chardan Capital upped their price target on Senti Biosciences from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, May 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Armistice Capital LLC bought a new position in Senti Biosciences in the second quarter valued at about $1,883,000. Geode Capital Management LLC lifted its stake in shares of Senti Biosciences by 395.6% in the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after purchasing an additional 117,588 shares during the period. Citadel Advisors LLC bought a new stake in shares of Senti Biosciences in the 3rd quarter valued at $117,000. Virtu Financial LLC bought a new stake in Senti Biosciences in the fourth quarter valued at $46,000. Finally, Jane Street Group LLC bought a new stake in Senti Biosciences in the 4th quarter valued at about $40,000. 25.70% of the stock is owned by institutional investors.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.